Wall Street analysts expect Medidata Solutions Inc (NASDAQ:MDSO) to announce earnings per share (EPS) of $0.31 for the current fiscal quarter, Zacks Investment Research reports. Six analysts have issued estimates for Medidata Solutions’ earnings. The lowest EPS estimate is $0.25 and the highest is $0.38. Medidata Solutions posted earnings of $0.33 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 6.1%. The firm is expected to issue its next quarterly earnings results on Thursday, February 8th.

According to Zacks, analysts expect that Medidata Solutions will report full-year earnings of $1.27 per share for the current financial year, with EPS estimates ranging from $1.21 to $1.34. For the next financial year, analysts anticipate that the firm will report earnings of $1.46 per share, with EPS estimates ranging from $1.31 to $1.61. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Medidata Solutions.

Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings data on Thursday, October 26th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.02. The firm had revenue of $140.08 million during the quarter, compared to analysts’ expectations of $141.27 million. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.28 earnings per share.

A number of equities analysts recently weighed in on the stock. SunTrust Banks restated a “buy” rating and set a $92.00 target price on shares of Medidata Solutions in a research report on Friday, October 27th. Wells Fargo & Co dropped their target price on shares of Medidata Solutions from $83.00 to $80.00 and set a “market perform” rating for the company in a research report on Friday, October 27th. Dougherty & Co assumed coverage on shares of Medidata Solutions in a research report on Thursday, November 2nd. They set a “neutral” rating for the company. Zacks Investment Research lowered shares of Medidata Solutions from a “hold” rating to a “sell” rating in a research report on Thursday, November 2nd. Finally, Royal Bank of Canada restated a “hold” rating and set a $80.00 target price on shares of Medidata Solutions in a research report on Friday, October 27th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $84.54.

In other Medidata Solutions news, EVP Michael I. Otner sold 10,000 shares of the stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $70.88, for a total transaction of $708,800.00. Following the completion of the transaction, the executive vice president now owns 80,674 shares in the company, valued at $5,718,173.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Rouven Bergmann sold 2,000 shares of the stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $65.40, for a total transaction of $130,800.00. Following the transaction, the chief financial officer now owns 91,775 shares of the company’s stock, valued at approximately $6,002,085. The disclosure for this sale can be found here. Insiders have sold 239,010 shares of company stock valued at $16,437,036 in the last quarter. 5.80% of the stock is owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Frontier Capital Management Co. LLC lifted its position in Medidata Solutions by 12.0% during the fourth quarter. Frontier Capital Management Co. LLC now owns 54,912 shares of the company’s stock valued at $3,480,000 after purchasing an additional 5,863 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its position in Medidata Solutions by 6.3% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 347,388 shares of the company’s stock valued at $22,014,000 after purchasing an additional 20,438 shares during the last quarter. Summit Creek Advisors LLC bought a new position in Medidata Solutions during the fourth quarter valued at $5,137,000. KAMES CAPITAL plc lifted its position in Medidata Solutions by 54.6% during the fourth quarter. KAMES CAPITAL plc now owns 25,521 shares of the company’s stock valued at $1,617,000 after purchasing an additional 9,012 shares during the last quarter. Finally, California Public Employees Retirement System lifted its position in Medidata Solutions by 1.2% during the third quarter. California Public Employees Retirement System now owns 104,076 shares of the company’s stock valued at $8,124,000 after purchasing an additional 1,276 shares during the last quarter.

Shares of Medidata Solutions (NASDAQ:MDSO) traded up $0.30 during trading hours on Friday, hitting $66.86. 584,347 shares of the company were exchanged, compared to its average volume of 330,994. The company has a current ratio of 1.29, a quick ratio of 3.37 and a debt-to-equity ratio of 0.61. Medidata Solutions has a 12-month low of $47.77 and a 12-month high of $85.92. The company has a market capitalization of $3,891.16, a price-to-earnings ratio of 95.52, a price-to-earnings-growth ratio of 3.45 and a beta of 1.69.

WARNING: This story was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://theolympiareport.com/2018/01/20/434943.html.

About Medidata Solutions

Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.

Get a free copy of the Zacks research report on Medidata Solutions (MDSO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.